scorecardresearch
Add as a preferred source on Google
Monday, February 23, 2026
TopicCadila Healthcare

Topic: Cadila Healthcare

Cadila looks to double its vaccine production as India battles to contain second Covid wave

The Indian drugmaker expects regulatory approval for its vaccine against Covid-19 by June. Efficacy readings from its last stage of clinical trials are expected in May.

Cadila to boost Covid vaccine production capacity by 70% if it passes human trials

Cadila is looking to hire contract manufacturers for additional 50-70 million doses of its vaccine, on top of 100 million that will come from its own capacity.

Kraft Heinz to sell some of its Indian businesses to Zydus for Rs 46 billion

Kraft to sell Complan, Glucon D & Nycil, among others to Zydus Wellness, in a deal estimated to be worth $625 million.

On Camera

Nick Jonas wearing a mangalsutra is validation for many Indians. He’s our favourite jiju

Nick Jonas is not trying to modernise the mangalsutra, but his gesture shows that choices can be equal. If commitment must be flaunted, it need not be gendered.

In the West, there’s anxiety. In India, optimism—Rishi Sunak says India poised to be leader in AI

On Wednesday, the former UK Prime Minister Rishi Sunak was speaking in New Delhi at a Carnegie & Observer Research Foundation event on AI.

Suspected brake failure leads to Tejas accident after landing, airframe likely to be written off

The IAF, so far, remains mum on this accident which has led to grounding of the fleet for safety checks.

No country is ever fully sovereign. Cold War era taught India its real meaning

India’s fraught neighbourhood places multiple constraints on its strategic choices. It leaves no time to take a deep breath, lean back and reset.